Key PointsQuestion
Is subclinical right ventricular dysfunction associated with heart failure risk among elderly persons?
Findings
In this secondary analysis of a community-based cohort study, subclinical right ventricular dysfunction assessed by 3-dimensional echocardiography was present in nearly one-fifth of elderly persons, was associated with common heart failure risk factors, and increased in prevalence with more advanced American College of Cardiology/American Heart Association heart failure stage. When identified, asymptomatic right ventricular dysfunction identified individuals at heightened risk for the development of heart failure hospitalization or death independent of left ventricular ejection fraction and N-terminal pro b-type natriuretic.
Meaning
These findings suggest an important and underrecognized role of right ventricular dysfunction in the progression to heart failure and the potential utility of 3-dimensional echocardiography to more accurately assess right ventricular performance.
Importance
Limited data exist on the prevalence and prognostic importance of right ventricular (RV) dysfunction for heart failure (HF) in the general population.
Objective
To assess the prevalence of RV dysfunction and its association with HF and mortality in a community-based elderly cohort.
Design, Setting, and Participants
Cross-sectional and time-to-event analysis of participants in the Atherosclerosis Risks in the Community (ARIC), a multicenter, population-based cohort study at the fifth study visit from 2011 to 2013, with a median follow-up of 4.1 years. This study included 1004 elderly participants in the ARIC study attending the fifth study visit who underwent both 3-dimensional and 2-dimensional RV echocardiography. Three-dimensional echocardiography data were analyzed between September 15, 2015, and July 24, 2016.
Exposures
Right ventricular ejection fraction (RVEF), RV–pulmonary artery (PA) coupling defined by the RVEF/PA systolic pressure (PASP) ratio, and RV longitudinal strain by 3-dimensional echocardiography.
Main Outcomes and Measures
For cross-sectional analysis, the prevalence of RV dysfunction across ACCF/AHA HF stages (0; A, at elevated risk for HF but without structural heart disease or clinical HF; B, structural heart disease but without clinical HF; and C, prevalent HF). For time-to-event analysis, a composite of incident HF hospitalization or all-cause death among participants free of HF at visit 5.
Results
Of the 1004 participants, mean (SD) age was 76 (5) years, 385 were men (38%), and 121 were black (12%). Mean (SD) RVEF was 53% (8%). Right ventricular EF, RVEF/PASP, and RV longitudinal strain were each progressively lower across advancing HF stages. Using reference limits from stage 0 participants, RVEF was abnormal in 103 asymptomatic persons with stage A HF (15%) and 27 with stage B HF (24%). Among participants free of HF at baseline, lower RVEF and worse RV-PA coupling (ie, lower RVEF/PASP ratio) both were associated with incident HF or death independent of LVEF and N-terminal pro b-type natriuretic peptide (hazard ratio, 1.20; 95% CI, 1.02-1.42 per 5% decrease in RVEF; P = .03; hazard ratio, 1.65, 95% CI, 1.15-2.37 per 0.5 unit decrease in RVEF/PASP ratio; P = .007).
Conclusions and Relevance
Right ventricular function and RV-PA coupling declined progressively across American College of Cardiology Foundation/American Heart Association HF stages. Among persons free of HF, lower RVEF was associated with incident HF or death independent of LVEF or N-terminal pro b-type natriuretic peptide.
Right ventricular (RV) dysfunction is prognostic of adverse outcomes independent of left ventricular (LV) dysfunction across a broad spectrum of cardiovascular diseases.1-9 Limited data exist regarding the prevalence and predictive value of RV dysfunction in the general population, particularly among elderly individuals, who are at a heightened risk for HF. Furthermore, the RV is highly afterload sensitive. Recognized age-associated increases in LV stiffness, LV filling pressure, and pulmonary pressure suggest that elderly individuals may be at particular risk for RV dysfunction owing to impaired RV–pulmonary artery (RV-PA) coupling.10 The RV has a complex 3-dimensional (3-D) shape, which makes accurate quantification of RV size and function challenging by 2-dimensional (2-D) echocardiography. Alternative approaches include cardiac magnetic resonance imaging (CMR),1 radionuclide ventriculography,2 or right heart catheterization,3,4 but are limited by cost, duration, radiation exposure, and invasiveness. Therefore, only limited community-based data are available regarding correlates and prognostic value of RV structure and function and RV-PA coupling.
Three-dimensional echocardiography allows for the direct quantification of RV volumes and RV ejection fraction (RVEF) without relying on geometric assumptions regarding RV shape. Right ventricular ejection fraction demonstrates good accuracy relative to CMR, as do RV volumes, particularly when not significantly enlarged.11-14 Professional guidelines now recommend the use of 3-D echocardiography in the assessment of RV disorders.15 We used 3-D echocardiography to determine the alterations in RV function across American College of Cardiology Foundation/American Heart Association (ACCF/AHA) HF stages and its prognostic relevance for incident HF or death among elderly participants in the community-based Atherosclerosis Risk in Communities (ARIC) study.16
The ARIC is a population-based cohort study from 4 US communities (Forsyth County, North Carolina; Jackson, Mississippi; Minneapolis, Minnesota; and Washington County, Maryland). The design and methods have been previously described.16 In brief, 15 792 middle-aged participants were enrolled between 1987 and 1989, and 6538 participants returned between 2011 and 2013 for a fifth study visit, at which time 2-D and 3-D echocardiography were performed.17 This study included the 1225 participants attending the fifth study visit who underwent 3-D and 2-D echocardiography with previously quantified 3-D LV and left arterial (LA) deformation.18,19 Of these participants, 1004 (82%) had optimal quality 3-D RV data (eFigure 1 in the Supplement). The study protocol was approved by institutional review boards at each field center, and additional approval was obtained by the ARIC steering committee. All participants provided written informed consent.
Design and methods of echocardiography in ARIC at visit 5 have been previously described in detail, including data on interobserver variability.17,19 Pulmonary artery systolic pressure (PASP) was calculated from the peak tricuspid regurgitation velocity by continuous wave Doppler as PASP = 4 × (peak velocityTR2) + 5.20-22 Mean pulmonary artery pressure (PAP) was calculated based on the tricuspid regurgitation velocity (TRV)–time integral as previously validated.22,23 Pulmonary vascular resistance (PVR) was estimated as 10 × TRV/VTIRVOT.24 Right ventricular stroke volume (SV) was calculated as RV end-diastolic volume (EDV) – RV end-systolic volume (ESV). Pulmonary capillary wedge pressure (PCWP) was estimated as PCWP = 11.96 + 0.596 × (E/e′septal).10 Right ventricular function was assessed based on the RV fractional area change, calculated as (RV end-diastolic area – RV end-systolic area)/RV end-diastolic area and tissue Doppler-based tricuspid annular peak systolic velocity.25
A full-volume echocardiography-gated 3-D data set was acquired from the apical position with a matrix-array 3-D transducer during breath hold with the highest frame rate achievable (20-26 Hz in our study), as previously described.19 This frame rate is in accordance with guideline recommendations,26 and higher than prior publications using this analysis software.11 Offline analysis was performed to measure RV volumes, RVEF, and RV freewall longitudinal strain (RVLS) using a semiautomatic algorithm (4-D RV-Function 2.0; TomTec Imaging Systems; Figure 1). The reproducibility and accuracy of this software when compared with CMR has been previously demonstrated.11
A single experienced cardiologist blinded to participant characteristics performed image quality assessment and subsequent analysis. Poor-quality data set was defined as significant acquisition artifacts (eg, stitch artifacts) or suboptimal endocardial definition. Quantitative measures were performed based on the recommendations of the American Society of Echocardiography.27 The RV-PA coupling was assessed as RVEF/PASP28,29 using PASP estimated by Doppler echocardiography and could be calculated in 728 participants owing to unmeasurable PASP in 276. Intraobserver variability of the 3-D echo-based RV measures was blindly assessed in 20 studies. The mean bias and coefficients of variation were RVEDV, −0.8 (95% CI, −4.2 to 2.6), 4.6%; RVESV, −1.38 (95% CI, −3.8 to 1.0), 8.2%; RVEF, 1.1 (95% CI, −1.5 to 3.7), 6.7%; and RVLS, −0.8 (−2.6 to 1.0), 8.0%.
Definitions of ACCF/AHA HF Stages
The ACCF/AHA HF stages were defined as follows: stage A (at elevated risk for HF but without structural heart disease or symptoms of HF), stage B (structural heart disease but without signs or symptoms of HF), and stage C (structural heart disease with earlier or current symptoms of HF).30-32 Stage 0 (low risk; free of HF risk factors or structural heart disease) was defined by the absence of criteria for stages A through C. Detailed definitions these stages in ARIC have been previously published30 and are provided in eTable 1 in the Supplement. Stage D was defined by therapy with an LV assist device or chronic intravenous inotropes. No participant was stage D.
Incident HF after visit 5 was based on HF hospitalization or HF death according to International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes (code 428 in any position) obtained by ARIC surveillance of hospital discharges.33 Deaths after visit 5 were ascertained by ARIC surveillance or the National Death Index.33
Clinical characteristics and 2-D/3-D echocardiographic measures were described by quartile of 3-D RVEF. Reference limits for 3-D measures were determined among stage 0 participants (low-risk; free of HF risk factors or structural heart disease) using quantile regression to define median, 10th, and 90th percentile limits with associated 95% confidence limits. Differences in 3-D RV measures and the prevalence of abnormal values between categories were assessed using multivariable linear and logistic regression models adjusting for age, sex, and race/ethnicity. The association between measures of RV function and a composite of HF hospitalization or all-cause death among participants free of prevalent HF at visit 5 was assessed using multivariable Cox regression models adjusted for age, sex, race/ethnicity, LVEF, and NT-proBNP. To assess the effect of potential selection bias related to unavailable 3-D RV measures owing to either unanalyzed or unanalyzable 3-D data or visit 5 nonattendance, we performed a sensitivity analysis using inverse probability of attrition weighting (IPAW) as detailed in eTables 2-5 in the Supplement.34,35 A 2-sided P value of less than .05 was considered statistically significant. All analyses were performed with Stata, version 15 (StataCorp).
The mean (SD) age of the 1004 study participants was 76 (5) years, 619 were women (62%), and 121 were black (12%). Two-dimensional echocardiography-based measures of RV size and function did not differ appreciably between participants at visit 5 included vs not included in this 3-D analysis (eTable 2 in the Supplement). Mean (SD) values in 3-D RVEF and RVLS were 53.2% (8.2%) and −27.1% (8.2%), respectively (eFigure 2 in the Supplement). Worse 3-D RVEF was associated with male sex, higher body mass index, higher prevalence of cardiovascular diseases including coronary disease, stroke, and atrial fibrillation, and higher high-sensitivity troponin-T concentrations (Table). Right ventricular ejection fraction was significantly, but modestly, associated with 2-D echo-based measures of RV function including RV fractional area change (r = 0.23; P < .001) and tricuspid annular s′ (r = 0.14; P < .001).
References limits for 3-D measures, determined based on the 10th percentile values from quantile regression in participants with stage 0 HF (n = 83; mean age, 74 years [range, 67-88 years], 60 women [72%], rate of death or HF, 0.3/100 person-year; 95% CI, 0.1-0.9) were as follows: RVEF, 45.4% (95% CI, 42.1% to 49.0%); RLVS, −21.9% (95% CI, −24.8% to −19.0%); RV end-diastolic volume, 50.0 mL/m2 (95% CI, 43.9 mL/m2 to 56.2 mL/m2); and RV end-systolic volume, 24.1 mL/m2 (20.1 mL/m2 to 28.2 mL/m2). Right ventricular ejection fraction was abnormal in 173 (17%) of the total study sample and RVLS was abnormal in 198 (20%) (eFigure 2 in the Supplement).
Physiologic Associations With RVEF
Mean (SD) PAP was 15.2 (3.4) mm Hg (>25 mm Hg in 0.4%) and mean (SD) PVR was 1.75 (0.41) WU (>2 WU in 15.4%). Higher PVR was significantly, although modestly, associated with lower RVEF, even after adjustment for PCWP (−3.18; 95% CI, −4.65 to −1.72; P < .001; eFigure 3A in the Supplement). No significant linear or nonlinear (data not shown) association was noted between RVEF and MPAP (eFigure 3B in the Supplement). The RVEF was directly associated with RV SV (R = 0.31, P < .001). Similar associations were noted for RVLS (eFigure 4 in the Supplement).
Lower RVEF was associated with greater LV mass, wall thickness, LA size, and lower TDI e′, even after adjusting for age, sex, race/ethnicity, and PVR (Table). Lower RVEF was also associated with larger LVESV and lower LVEF, longitudinal strain, twist, and torsion (Table). Right ventricular LS demonstrated similar associations with LV structure and function (Figure 2B; eFigure 4 in the Supplement). Concordant findings were observed in IPAW analysis (eTable 3 in the Supplement).
RV Structure and Function Across HF Stages
Eighty-three participants (8%) were classified as stage 0, 676 (67%) were stage A, 114 (11%) were stage B, and 131 (13%) were stage C. Across HF stages, significant trends were observed for higher RV volumes, lower RVEF, and worse RVLS (Figure 2; eFigure 5 in the Supplement), with progressive decrements noted in stage A and stage B HF. Right ventricular–PA coupling, assessed as the RVEF/PASP ratio, also declined across HF stages consistent with worse RV systolic function accounting for RV afterload. The highest prevalence of RV dysfunction was in stage C, among whom RVEF was abnormally low in 28 (25%) and RVLS was impaired in 49 (37%) (Figure 3). Similar findings were observed in sensitivity analyses incorporating inverse probability weights (eTable 4 in the Supplement).
Association of RV Function With All-Cause Mortality or Incident HF
Of the 847 participants free of prevalent HF at visit 5, 59 (7.0%) experienced the composite outcome of incident HF hospitalization or all-cause mortality during a median follow-up of 4.1 years (25th and 75th percentile limits, 3.8-4.3 years). Lower RVEF at visit 5 was significantly and linearly associated with a higher event rate during follow-up (Figure 4A). After adjustment for age, sex, race/ethnicity, LVEF, and NT-proBNP, each 5% decrease in RVEF was associated with a 20% increase in the hazard for death or HF hospitalization (adjusted HR per 5% decrease in RVEF, 1.20; 95% CI, 1.02-1.42; P = .03; Figure 4A). This association remained significant after further adjusting for left atrial volume index (HR, 1.20; 95% CI, 1.02-1.42; P = .03) or E/e′ (HR, 1.18; 95% CI, 1.00-1.40; P = .05). Lower RVEF/PASP ratio, reflecting worse RV-PA coupling, was also associated with a higher risk of death or incident HF (demographic, LVEF, and NT-proBNP–adjusted HR per 0.5 unit decrease, 1.58; 95% CI, 1.10-2.28; P = .01; Figure 4B), which persisted after further adjustment for left atrial volume index (HR, 1.59; 95% CI, 1.10-2.30; P = .01) or E/e′ (HR, 1.58; 95% CI, 1.09-2.29; P = .02). Similar findings were observed in IPAW analyses (eTable 5 in the Supplement). Right ventricular LS was not significantly associated with risk of incident HF or death (HR per 1% decrease, 1.03; 95% CI, 0.99-1.07; P = .14 adjusting for age, sex, and race/ethnicity). Furthermore, no significant association with death or incident HF was noted for RV fractional area change (HR per 1% decrease, 1.02; 95% CI, 0.99-1.06; P = .22) or tricuspid annular s′ (HR per 1 cm/s decrease, 1.07; 95% CI, 0.96-1.19; P = .23) after adjustment for age, sex, race/ethnicity, and LVEF.
In what is, to our knowledge, one of largest studies to quantify RV function (RVEF and RVLS) and RV-PA coupling (RVEF/PASP ratio) in a community-based sample, our study provides important, novel insights into the potential predictors of RV dysfunction and its association with HF risk. We report 3 novel findings: first, RV systolic function and RV-PA coupling decline progressively across ACCF/AHA HF stages, and RV function is impaired in nearly one-fourth of asymptomatic persons with stage B HF. Second, while RVEF is inversely associated with RV afterload, it is also associated directly with LV function independent of pulmonary vascular measures, suggesting parallel alterations in biventricular function. Third, among persons free of HF, both worse RVEF and worse RV-PA coupling are linearly associated with heighted risk of incident HF or death independent of LVEF, NT-proBNP, and measures of LV filling pressure. These associations were not observed for RV function assessed by RV fractional area change and tricuspid annular s′. These data suggest an important and underrecognized role of RV dysfunction in the progression to HF and suggest the potential utility of 3-D echocardiography to more accurately assess RV performance.
Previous studies of RV function have typically focused on patients with established cardiovascular disease, including HF,2-6 myocardial infarction,1 or pulmonary arterial hypertension.7-9 The relatively few studies to assess the RV in general population samples have generally used 2-D echocardiography,10,36 which is of limited accuracy and precision. Three-dimensional echocardiography uniquely allows for the acquisition of a 3-D volumetric data set from which RV volumes and EF can be quantified without geometric assumptions.11-14 However, 3-D echocardiographic RV assessment in previous general population studies has focused primarily on normal values for 3-D RVEF and volumes in younger healthy samples (typically aged 45-48 years),37,38 with scarce data on RV performance in elderly individuals and its association with HF risk. Among our large community-based elderly sample, we identified 83 participants free of cardiovascular disease or risk factors. Reference limits for RVEF (>45.5%) and RVLS (<21.9%) derived from this subgroup using quantile regression were consisted with a previous study in a healthy sample (n = 37, age >70 years)37 and with professional guidelines (RVEF <45%; GLS <20%).15
The RV is known to be particularly afterload sensitive, such that RVEF is inversely associated with MPAP or PVR in conditions such as pulmonary arterial hypertension or advanced HF with reduced LVEF.4,39 In our study, lower RVEF was associated with higher RV afterload as assessed by PVR and also with lower RV stroke volume, possibly explaining its lack of association with flow-dependent measures of afterload such as PA pressure. Lower RVEF and RVLS were also associated with worse LV systolic function (higher LV end-systolic volume, lower LVEF, and worse GLS) and LV diastolic function (larger LA size and lower e′). Importantly, these associations remained significant after accounting for pulmonary vascular measures, suggesting that greater RV afterload secondary to elevated LV filling pressure does not fully account for these associations. This is consistent with prior studies that identify RV dysfunction in early stage hypertension40 and obesity41 in absence of pulmonary hypertension, that demonstrate coupled impairments of RV and LV function independent of PAP in LV pressure overload42 and atrial fibrillation,43 and that suggest an important role for the interventricular septum40 and LV free wall44 in RV systolic function. Furthermore, we observed progressive decline in RV-PA coupling across HF stages, suggesting worsening RV contractility at any given afterload at greater HF stages, consistent with data suggesting higher afterload sensitivity of the RV in HFpEF.45 Together, these findings suggest parallel effects on biventricular function independent of the pulmonary vasculature.
The ACCF/AHA construct of HF stages was introduced to emphasize the progressive nature of HF, whereby risk factors promote detrimental alterations in cardiac structure and function, which in turn underlie clinical symptomatic HF. While the LV has been the primary focus for these cardiac alterations, we demonstrate that RV size increases and RV function, as reflected in RVEF, RVLS, and RV-PA coupling, decreases across HF stages. The prevalence of impaired RVEF increased by nearly 3-fold from stage 0 to stage B HF (asymptomatic stages) and was abnormal in one-fourth of stage B participants. We also demonstrate that reductions in RVEF in these asymptomatic stages (0 through B) are prognostically relevant, with each 5% decrease in RVEF associated with a 20% increase risk of death or HF hospitalization independent of demographics, LVEF, and NT-proBNP. Impaired RV-PA coupling also decreased with more advanced HF stage, was impaired in nearly one-half of stage C participants, and, among HF-free participants, was independently associated with incident HF or death. As PA pressure also increases across HF stages and is associated with incident HF, these findings support the importance of primary RV dysfunction, accounting for afterload, for HF.
By demonstrating the prognostic importance of alterations in RV function in a population-based sample, our findings extend on CMR-based data from the Multi-Ethnic Study of Atherosclerosis showing the association of greater RV mass with increased risk of HF or cardiovascular death.46 A 2017 study of 446 patients47 with prevalent cardiovascular disease (ischemic and valvular heart disease, cardiomyopathy, and pulmonary hypertension) demonstrated an association of lower RVEF by 3-D echocardiography with the composite of cardiac death, nonfatal myocardial infarction, ventricular fibrillation, and HF hospitalization.47 We now extend the prognostic relevance of RVEF to a community-based sample, largely free of prevalent cardiovascular disease, and focus on HF as a particularly relevant end point.
Several limitations of this analysis should be noted. Of ARIC participants alive at the fifth visit, 6538 (64%) attended, which may have introduced ascertainment bias. Quantitative 3-D echocardiographic data on the RV were available in a relatively small proportion of participants attending visit 5, which may result in further selection bias. However, sensitivity analysis by IPAW provided consistent findings (eTable 2-5 in the Supplement), suggesting that the influence of bias on our findings is small, and among visit 5 attendees, RV size and function assessed by 2-D echocardiography did not differ clinically between those included vs not included in this 3-D analysis (eTable 2 in the Supplement). Second, we were not able to provide reference limits based on sex owing to the small number of men in stage 0. However, our use of indexed values for volumes should have minimized expected sex-based differences, and our reference values generally align with those of prior studies and guidelines.15 Third, M-mode of the tricuspid annular was not acquired in ARIC at visit 5, and therefore we were not able to evaluate the association of the tricuspid annular plane systolic excursion (TAPSE) or the TAPSE/PASP ratio with HF stages or incident HF or death. The TAPSE/PASP ratio is one of the most commonly used echocardiographic measures of RV-PA coupling, and we are unable to evaluate its performance relative to 3-D echocardiography-based RVEF/PASP ratio. However, TAPSE was initially validated against RVEF,48 and the RVEF/PASP ratio has previously been used as a measure of RV-PA coupling.28,29 Follow-up time after echocardiography at visit 5 was relatively short (median, 4.1 years) and the number of events relatively small (n = 59), which limited our power to assess the incremental prognostic value of 3-D echocardiographic measures of RV function over conventional echocardiographic measures. We were also unable to adjust for comorbidities, such as obesity, coronary disease, and atrial fibrillation, that were associated with RV functional measures and are established risk factors for HF. We therefore could not determine the prognostic relevance of RV dysfunction independent of these comorbidities, although RV dysfunction itself may be one means by which these comorbidities increase HF risk. Three-dimensional echocardiography-based RVLS did not demonstrate clear advantages vs 3-D RVEF in this study. However, the relatively low frame rates for 3-D images (20-26 Hz) compared with those for 2-D echocardiography (50-80 Hz) may have resulted in reduced sensitivity and/or precision of 3-D–based RVLS. While our data are not sufficient to demonstrate superiority of 3-D compared with 2-D echocardiography-based RV assessments to predict HF, they support further studies evaluating the utility of 3-D echocardiography to detect RV dysfunction and risk for HF.
In a large, community-based cohort of older persons, RV function and RV-PA coupling declined progressively across ACCF/AHA HF stages, with a nearly 3-fold increase in prevalence RV dysfunction from stage 0 to stage B HF, and is impaired in more than one-fourth of asymptomatic persons with stage B HF. Among persons free of HF, lower RVEF and lower RVEF/PASP ratio are linearly associated with a heighted risk of incident HF or death independent of LVEF and NT-proBNP. These data suggest an important and underrecognized role of RV dysfunction in the progression to HF and suggest the potential utility of 3-D echocardiography to more accurately assess RV performance.
Corresponding Author: Amil M. Shah, MD, MPH, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02445 (ashah11@partners.org).
Accepted for Publication: June 25, 2018.
Published Online: August 15, 2018. doi:10.1001/jamacardio.2018.2454
Author Contributions: Drs Nochioka and Shah had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Nochioka, Querejeta Roca, Hung, Solomon, Kitzman, Shah.
Acquisition, analysis, or interpretation of data: Nochioka, Querejeta Roca, Claggett, Biering-Sørensen, Matsushita, Kitzman, Shah.
Drafting of the manuscript: Nochioka, Hung, Shah.
Critical revision of the manuscript for important intellectual content: Nochioka, Querejeta Roca, Claggett, Biering-Sørensen, Matsushita, Solomon, Kitzman, Shah.
Statistical analysis: Nochioka, Querejeta Roca, Claggett, Shah.
Obtained funding: Solomon, Shah.
Administrative, technical, or material support: Biering-Sørensen, Shah.
Supervision: Querejeta Roca, Claggett, Hung, Solomon, Kitzman, Shah.
Other - supervision of echo technicians: Matsushita.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Shah reports receiving research support from Novartis and consulting fees from Myokardia, GlaskoSmithKline, and Philips. No other disclosures are reported.
Funding/Support: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268 201100012C. The work for this article was also supported by National Heart, Lung, and Blood Institute grants K08HL116792 and R01HL135008 (Dr Shah), American Heart Association grant 14CRP20380422 (Dr Shah), and a Watkins Discovery Award from the Brigham and Women’s Heart and Vascular Center (Dr Shah).
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the staff and participants of the Atherosclerosis Risk in Communities Study for their important contributions.
1.Larose
E, Ganz
P, Reynolds
HG,
et al. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction.
J Am Coll Cardiol. 2007;49(8):855-862.
PubMedGoogle ScholarCrossref 2.Meyer
P, Filippatos
GS, Ahmed
MI,
et al. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure.
Circulation. 2010;121(2):252-258.
PubMedGoogle ScholarCrossref 3.Juillière
Y, Barbier
G, Feldmann
L, Grentzinger
A, Danchin
N, Cherrier
F. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy.
Eur Heart J. 1997;18(2):276-280.
PubMedGoogle ScholarCrossref 4.de Groote
P, Millaire
A, Foucher-Hossein
C,
et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure.
J Am Coll Cardiol. 1998;32(4):948-954.
PubMedGoogle ScholarCrossref 5.Melenovsky
V, Hwang
SJ, Lin
G, Redfield
MM, Borlaug
BA. Right heart dysfunction in heart failure with preserved ejection fraction.
Eur Heart J. 2014;35(48):3452-3462.
PubMedGoogle ScholarCrossref 6.Mohammed
SF, Hussain
I, AbouEzzeddine
OF,
et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study.
Circulation. 2014;130(25):2310-2320.
PubMedGoogle ScholarCrossref 7.McLaughlin
VV, Archer
SL, Badesch
DB,
et al; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association.
Circulation. 2009;119(16):2250-2294.
PubMedGoogle ScholarCrossref 8.Eysmann
SB, Palevsky
HI, Reichek
N, Hackney
K, Douglas
PS. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension.
Circulation. 1989;80(2):353-360.
PubMedGoogle ScholarCrossref 9.Ghio
S, Klersy
C, Magrini
G,
et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension.
Int J Cardiol. 2010;140(3):272-278.
PubMedGoogle ScholarCrossref 10.Lam
CS, Borlaug
BA, Kane
GC, Enders
FT, Rodeheffer
RJ, Redfield
MM. Age-associated increases in pulmonary artery systolic pressure in the general population.
Circulation. 2009;119(20):2663-2670.
PubMedGoogle ScholarCrossref 11.Medvedofsky
D, Addetia
K, Patel
AR,
et al. Novel approach to three-dimensional echocardiographic quantification of right ventricular volumes and function from focused views.
J Am Soc Echocardiogr. 2015;28(10):1222-1231.
PubMedGoogle ScholarCrossref 12.van der Zwaan
HB, Geleijnse
ML, McGhie
JS,
et al. Right ventricular quantification in clinical practice: two-dimensional vs. three-dimensional echocardiography compared with cardiac magnetic resonance imaging.
Eur J Echocardiogr. 2011;12(9):656-664.
PubMedGoogle ScholarCrossref 13.Nesser
HJ, Tkalec
W, Patel
AR,
et al. Quantitation of right ventricular volumes and ejection fraction by three-dimensional echocardiography in patients: comparison with magnetic resonance imaging and radionuclide ventriculography.
Echocardiography. 2006;23(8):666-680.
PubMedGoogle ScholarCrossref 14.Leibundgut
G, Rohner
A, Grize
L,
et al. Dynamic assessment of right ventricular volumes and function by real-time three-dimensional echocardiography: a comparison study with magnetic resonance imaging in 100 adult patients.
J Am Soc Echocardiogr. 2010;23(2):116-126.
PubMedGoogle ScholarCrossref 15.Lang
RM, Badano
LP, Mor-Avi
V,
et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Eur Heart J Cardiovasc Imaging. 2015;16(3):233-270.
PubMedGoogle ScholarCrossref 16.The ARIC investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives.
Am J Epidemiol. 1989;129(4):687-702.
PubMedGoogle ScholarCrossref 17.Shah
AM, Cheng
S, Skali
H,
et al. Rationale and design of a multicenter echocardiographic study to assess the relationship between cardiac structure and function and heart failure risk in a biracial cohort of community-dwelling elderly persons: the Atherosclerosis Risk in Communities study.
Circ Cardiovasc Imaging. 2014;7(1):173-181.
PubMedGoogle ScholarCrossref 18.Gonçalves
A, Hung
CL, Claggett
B,
et al. Left atrial structure and function across the spectrum of cardiovascular risk in the elderly: the atherosclerosis risk in communities study.
Circ Cardiovasc Imaging. 2016;9(2):e004010.
PubMedGoogle ScholarCrossref 19.Hung
C-L, Gonçalves
A, Shah
AM, Cheng
S, Kitzman
D, Solomon
SD. Age- and sex-related influences on left ventricular mechanics in elderly individuals free of prevalent heart failure: the ARIC study (Atherosclerosis Risk in Communities).
Circ Cardiovasc Imaging. 2017;10(1):e004510.
PubMedGoogle ScholarCrossref 20.Yock
PG, Popp
RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation.
Circulation. 1984;70(4):657-662.
PubMedGoogle ScholarCrossref 21.Currie
PJ, Seward
JB, Chan
KL,
et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients.
J Am Coll Cardiol. 1985;6(4):750-756.
PubMedGoogle ScholarCrossref 22.van Riel
AC, Opotowsky
AR, Santos
M,
et al. Accuracy of echocardiography to estimate pulmonary artery pressures with exercise: a simultaneous invasive-noninvasive comparison.
Circ Cardiovasc Imaging. 2017;10(4):e005711.
PubMedGoogle ScholarCrossref 23.Aduen
JF, Castello
R, Lozano
MM,
et al. An alternative echocardiographic method to estimate mean pulmonary artery pressure: diagnostic and clinical implications.
J Am Soc Echocardiogr. 2009;22(7):814-819.
PubMedGoogle ScholarCrossref 24.Abbas
AE, Fortuin
FD, Schiller
NB, Appleton
CP, Moreno
CA, Lester
SJ. A simple method for noninvasive estimation of pulmonary vascular resistance.
J Am Coll Cardiol. 2003;41(6):1021-1027.
PubMedGoogle ScholarCrossref 25.Rudski
LG, Lai
WW, Afilalo
J,
et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.
J Am Soc Echocardiogr. 2010;23(7):685-713.
PubMedGoogle ScholarCrossref 26.Lang
RM, Badano
LP, Mor-Avi
V,
et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
J Am Soc Echocardiogr. 2015;28(1):1-39.e14.
PubMedGoogle ScholarCrossref 27.Picard
MH, Adams
D, Bierig
SM,
et al; American Society of Echocardiography. American Society of Echocardiography recommendations for quality echocardiography laboratory operations.
J Am Soc Echocardiogr. 2011;24(1):1-10.
PubMedGoogle ScholarCrossref 28.van de Veerdonk
MC, Kind
T, Marcus
JT,
et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.
J Am Coll Cardiol. 2011;58(24):2511-2519.
PubMedGoogle ScholarCrossref 29.Kubba
S, Davila
CD, Forfia
PR. Methods for evaluating right ventricular function and ventricular-arterial coupling.
Prog Cardiovasc Dis. 2016;59(1):42-51.
PubMedGoogle ScholarCrossref 30.Shah
AM, Claggett
B, Loehr
LR,
et al. Heart failure stages among older adults in the community: the Atherosclerosis Risk in Communities Study.
Circulation. 2017;135(3):224-240.
PubMedGoogle ScholarCrossref 31.Yancy
CW, Jessup
M, Bozkurt
B,
et al; WRITING COMMITTEE MEMBERS; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Circulation. 2013;128(16):e240-e327.
PubMedGoogle Scholar 32.Ponikowski
P, Voors
AA, Anker
SD,
et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Eur Heart J. 2016;37(27):2129-2200.
PubMedGoogle ScholarCrossref 33.Loehr
LR, Rosamond
WD, Chang
PP, Folsom
AR, Chambless
LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study).
Am J Cardiol. 2008;101(7):1016-1022.
PubMedGoogle ScholarCrossref 34.Weuve
J, Tchetgen Tchetgen
EJ, Glymour
MM,
et al. Accounting for bias due to selective attrition: the example of smoking and cognitive decline.
Epidemiology. 2012;23(1):119-128.
PubMedGoogle ScholarCrossref 35.Gottesman
RF, Rawlings
AM, Sharrett
AR,
et al. Impact of differential attrition on the association of education with cognitive change over 20 years of follow-up: the ARIC neurocognitive study.
Am J Epidemiol. 2014;179(8):956-966.
PubMedGoogle ScholarCrossref 36.Lindqvist
P, Waldenström
A, Henein
M, Mörner
S, Kazzam
E. Regional and global right ventricular function in healthy individuals aged 20-90 years: a pulsed Doppler tissue imaging study: Umeå General Population Heart Study.
Echocardiography. 2005;22(4):305-314.
PubMedGoogle ScholarCrossref 37.Maffessanti
F, Muraru
D, Esposito
R,
et al. Age-, body size-, and sex-specific reference values for right ventricular volumes and ejection fraction by three-dimensional echocardiography: a multicenter echocardiographic study in 507 healthy volunteers.
Circ Cardiovasc Imaging. 2013;6(5):700-710.
PubMedGoogle ScholarCrossref 38.Tamborini
G, Marsan
NA, Gripari
P,
et al. Reference values for right ventricular volumes and ejection fraction with real-time three-dimensional echocardiography: evaluation in a large series of normal subjects.
J Am Soc Echocardiogr. 2010;23(2):109-115.
PubMedGoogle ScholarCrossref 39.Nienaber
CA, Spielmann
RP, Wasmus
G, Montz
R, Mathey
DG, Bleifeld
W. Right ventricular ejection fraction from equilibrium krypton-81m blood pool scans: a noninvasive predictor of pulmonary arterial hypertension.
Eur Heart J. 1987;8(3):297-307.
PubMedGoogle ScholarCrossref 40.Pedrinelli
R, Canale
ML, Giannini
C,
et al. Right ventricular dysfunction in early systemic hypertension: a tissue Doppler imaging study in patients with high-normal and mildly increased arterial blood pressure.
J Hypertens. 2010;28(3):615-621.
PubMedGoogle ScholarCrossref 41.McCabe
C, Oliveira
RKF, Rahaghi
F,
et al. Right ventriculo-arterial uncoupling and impaired contractile reserve in obese patients with unexplained exercise intolerance.
Eur J Appl Physiol. 2018;118(7):1415-1426.
PubMedGoogle ScholarCrossref 42.Gottdiener
JS, Gay
JA, Maron
BJ, Fletcher
RD. Increased right ventricular wall thickness in left ventricular pressure overload: echocardiographic determination of hypertrophic response of the “nonstressed” ventricle.
J Am Coll Cardiol. 1985;6(3):550-555.
PubMedGoogle ScholarCrossref 43.Cohen
S, Gaddam
S, Gemignani
A, Wu
WC, Sharma
S, Choudhary
G. Right ventricular function relates to functional capacity in men with atrial fibrillation and preserved left ventricular ejection fraction.
Echocardiography. 2013;30(5):542-550.
PubMedGoogle ScholarCrossref 45.Borlaug
BA, Kane
GC, Melenovsky
V, Olson
TP. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.
Eur Heart J. 2016;37(43):3293-3302.
PubMedGoogle ScholarCrossref 46.Kawut
SM, Barr
RG, Lima
JA,
et al. Right ventricular structure is associated with the risk of heart failure and cardiovascular death: the Multi-Ethnic Study of Atherosclerosis (MESA)--right ventricle study.
Circulation. 2012;126(14):1681-1688.
PubMedGoogle ScholarCrossref 47.Nagata
Y, Wu
VC, Kado
Y,
et al. Prognostic value of right ventricular ejection fraction assessed by transthoracic 3D echocardiography.
Circ Cardiovasc Imaging. 2017;10(2):e005384.
PubMedGoogle ScholarCrossref 48.Kaul
S, Tei
C, Hopkins
JM, Shah
PM. Assessment of right ventricular function using two-dimensional echocardiography.
Am Heart J. 1984;107(3):526-531.
PubMedGoogle ScholarCrossref